PD-1 and PD-L1 inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “PD-1 and PD-L1 inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in PD-1 and PD-L1 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
PD-1 and PD-L1 inhibitors: Overview
PD-1 and PD-L1/PD-L2 belong to the family of immune checkpoint proteins that act as co-inhibitory factors that can limit the development of the T cell response. The PD-1 (programmed cell death-1) receptor is expressed on the surface of activated T cells. Its ligands, PD-L1 and PD-L2, are expressed on the surface of dendritic cells or macrophages. The PD-1/PD-L1 interaction ensures that the immune system is activated only at the appropriate time in order to minimize the possibility of chronic autoimmune inflammation. The PD-1/PD-L1 pathway represents an adaptive immune resistance mechanism exerted by tumor cells in response to endogenous immune anti-tumor activity. PD-L1 is overexpressed on tumor cells or on non-transformed cells in the tumor microenvironment. PD-L1 expressed on the tumor cells binds to PD-1 receptors on the activated T cells, which leads to the inhibition of the cytotoxic T cells. Monoclonal antibodies specific to the PD-1 and PD-L1 immune checkpoints have been approved for the treatment of various tumors. PD-1/PD-L1 inhibitors may be combined with other immunotherapies or traditional treatments to enhance efficacy relative to that using PD-1/PD-L1 therapy alone.
Report Highlights
This segment of the PD-1 and PD-L1 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
PD-1 and PD-L1 inhibitors Emerging Drugs
Further product details are provided in the report……..
PD-1 and PD-L1 inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different PD-1 and PD-L1 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
PD-1 and PD-L1 inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses PD-1 and PD-L1 inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PD-1 and PD-L1 inhibitors drugs.
PD-1 and PD-L1 inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “PD-1 and PD-L1 inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in PD-1 and PD-L1 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
PD-1 and PD-L1 inhibitors: Overview
PD-1 and PD-L1/PD-L2 belong to the family of immune checkpoint proteins that act as co-inhibitory factors that can limit the development of the T cell response. The PD-1 (programmed cell death-1) receptor is expressed on the surface of activated T cells. Its ligands, PD-L1 and PD-L2, are expressed on the surface of dendritic cells or macrophages. The PD-1/PD-L1 interaction ensures that the immune system is activated only at the appropriate time in order to minimize the possibility of chronic autoimmune inflammation. The PD-1/PD-L1 pathway represents an adaptive immune resistance mechanism exerted by tumor cells in response to endogenous immune anti-tumor activity. PD-L1 is overexpressed on tumor cells or on non-transformed cells in the tumor microenvironment. PD-L1 expressed on the tumor cells binds to PD-1 receptors on the activated T cells, which leads to the inhibition of the cytotoxic T cells. Monoclonal antibodies specific to the PD-1 and PD-L1 immune checkpoints have been approved for the treatment of various tumors. PD-1/PD-L1 inhibitors may be combined with other immunotherapies or traditional treatments to enhance efficacy relative to that using PD-1/PD-L1 therapy alone.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence PD-1 and PD-L1 inhibitors R&D. The therapies under development are focused on novel approaches for PD-1 and PD-L1 inhibitors.
This segment of the PD-1 and PD-L1 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
PD-1 and PD-L1 inhibitors Emerging Drugs
- Tislelizumab: BeiGene
- Dostarlimab: GlaxoSmithKline
Further product details are provided in the report……..
PD-1 and PD-L1 inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different PD-1 and PD-L1 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on PD-1 and PD-L1 inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
PD-1 and PD-L1 inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses PD-1 and PD-L1 inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PD-1 and PD-L1 inhibitors drugs.
PD-1 and PD-L1 inhibitors Report Insights
- PD-1 and PD-L1 inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing PD-1 and PD-L1 inhibitors drugs?
- How many PD-1 and PD-L1 inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for PD-1 and PD-L1 inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the PD-1 and PD-L1 inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for PD-1 and PD-L1 inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- BeiGene
- GlaxoSmithKline
- Shanghai Junshi Biosciences
- Merck & Co
- Innovent Biologics
- Phio Pharmaceuticals
- Curocell
- Oneness Biotech
- Seneca Therapeutics
- Lyvgen Biopharma
- Jiangsu Hengrui Medicine
- Curis
- Sinocelltech
- Taizhou HoudeAoke Biomedical
- Y-Biologics
- Merck KGaA
- Celgene
- MedImmune
- Genentech
- Tislelizumab
- Dostarlimab
- Toripalimab
- Pembrolizumab
- IBI-318
- PH 762-TME
- CRC-01
- SNA-01
- SVV-012
- Research programme: bispecific antibodies
- Camrelizumab
- Carrizumab
- CA-170
- SNA-02
- SCT-B07
- LP 002
- YBL-027
- Avelumab
- Durvalumab
- Atezolizumab
Introduction
Executive Summary
PD-1 and PD-L1 inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
PD-1 and PD-L1 inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
PD-1 and PD-L1 inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
PD-1 and PD-L1 inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Registration)
Comparative Analysis
Dostarlimab: GlaxoSmithKline
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tislelizumab: BeiGene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
PH 762-TME: Phio Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
PD-1 and PD-L1 inhibitors Key Companies
PD-1 and PD-L1 inhibitors Key Products
PD-1 and PD-L1 inhibitors- Unmet Needs
PD-1 and PD-L1 inhibitors- Market Drivers and Barriers
PD-1 and PD-L1 inhibitors- Future Perspectives and Conclusion
PD-1 and PD-L1 inhibitors Analyst Views
PD-1 and PD-L1 inhibitors Key Companies
Appendix
Executive Summary
PD-1 and PD-L1 inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
PD-1 and PD-L1 inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
PD-1 and PD-L1 inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
PD-1 and PD-L1 inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Registration)
Comparative Analysis
Dostarlimab: GlaxoSmithKline
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Tislelizumab: BeiGene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
PH 762-TME: Phio Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
PD-1 and PD-L1 inhibitors Key Companies
PD-1 and PD-L1 inhibitors Key Products
PD-1 and PD-L1 inhibitors- Unmet Needs
PD-1 and PD-L1 inhibitors- Market Drivers and Barriers
PD-1 and PD-L1 inhibitors- Future Perspectives and Conclusion
PD-1 and PD-L1 inhibitors Analyst Views
PD-1 and PD-L1 inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for PD-1 and PD-L1 inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for PD-1 and PD-L1 inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for PD-1 and PD-L1 inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for PD-1 and PD-L1 inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
